Recent performance snapshot Biogen (BIIB) shares closed at US$171.59, with performance mixed across recent periods. The stock ...

Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Earnings Yield Investor model based on the published strategy of ...

Biogen's investigational drug litifilimab has received FDA Breakthrough Therapy Designation for treating cutaneous lupus ...

If you are wondering whether Biogen’s current share price still offers value, or if the recent run has already priced in the good news, this article is for you. Biogen closed at US$185.63, with ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been given a consensus rating of “Hold” by the thirty-one brokerages that are covering the firm, MarketBeat.com reports. Eighteen analysts have rated ...

Biogen BIIB announced that the FDA has granted the Breakthrough Therapy designation to its investigational, first-in-class, ...

A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides ...

UCB SA (OTC:UCBJY) (OTC:UCBJF) (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) on Thursday presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab ...

Biogen Inc's (NYSE: BIIB) short interest as a percent of float has fallen 32.24% since its last report. According to exchange reported data, there are now 4.47 million shares sold short, which is 3.93 ...